Abiopharma

Best Canon Printer Models for Home and Office Use in 2025

Nieuwe gegevens uit het baanbrekende HELIOS-B fase 3-onderzoek, gepresenteerd tijdens het ESC-congres 2025, laten het langetermijnvoordeel zien van vutrisiran voor het cardiovasculaire systeem bij ATTR-CM

I nuovi dati dellimportante studio di fase 3 HELIOS-B presentati al Congresso ESC 2025 dimostrano il beneficio cardiovascolare a lungo termine del vutrisiran nella ATTR-CM

Los nuevos datos del importante estudio HELIOS-B de fase III presentados en el ESC Congress 2025 demuestran los beneficios cardiovasculares a largo plazo de vutrisiran en la IC-ATTR

De nouvelles données issues de l’étude de phase 3 HELIOS-B, présentées lors du congrès ESC 2025, démontrent les bénéfices cardiovasculaires à long terme du vutrisiran dans le traitement de l’ATTR-CM

Alnylam wird Zilebesiran in eine globale Phase-3-Studie zu kardiovaskulären Endpunkten weiterentwickeln

Johnson & Johnson - New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

Zai Lab Announces Participation in Investor Conferences in September 2025

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM